The University of Chicago is one of 152 locations participating in Gilead's trial involving severe COVID-19 patients, which is "single arm" meaning it does not measure the drug against a matched group of patients treated with a placebo. A trial of patients with moderate COVID-19 symptoms has 169 study locations. STAT reported that UChicago Medicine recruited 113 people with severe COVID-19 into Gilead's trial. The New England Journal of Medicine last week published an analysis showing that two-thirds of a small group of severely ill COVID-19 patients saw their condition improve after treatment with remdesivir. Those results are not expected until after Gilead's trial reads out.

Source: bd News24 April 17, 2020 02:03 UTC